Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) ended Thursday session in red amid volatile trading. The shares closed down -0.05 points or -0.51% at $9.70 with 156,612.00 shares getting traded. Post opening the session at $9.80, the shares hit an intraday low of $9.65 and an intraday high of $9.90 and the price vacillated in this range throughout the day. The company has a market cap of $481.94 million and the numbers of outstanding shares have been calculated to be 49.94 million shares.
SciClone Pharmaceuticals, Inc. (SCLN) announced two important achievements in advancing the Company’s clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN® in sepsis, a life-threatening infectious disease in which the drug has previously demonstrated therapeutic benefit in a Phase 2 clinical trial. The sepsis trial is a major component of SciClone’s strategy to grow ZADAXIN sales in the indications for which it is approved, as well as new indications. In addition, the first patient has been treated in the Phase 1 trial of PT-112, a multi-targeted platinum-pyrophosphate anticancer agent being developed for patients with advanced solid tumors. PT-112 is a key early-stage asset supporting SciClone’s strategy to expand its oncology portfolio and drive long-term growth.
Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) ended Thursday session in green amid volatile trading. The shares closed up +0.10 points or 3.23% at $3.20 with 152,381.00 shares getting traded. Post opening the session at $3.10, the shares hit an intraday low of $3.05 and an intraday high of $3.20 and the price vacillated in this range throughout the day. The company has a market cap of $136.21 million and the numbers of outstanding shares have been calculated to be 45.31 million shares.
AcelRx Pharmaceuticals Inc (ACRX) announced the initiation of the Phase 3 IAP312 study of Zalviso® (sufentanil sublingual tablet system), an investigational product candidate being developed for the management of moderate-to-severe acute pain in adult patients in a hospital setting. IAP312 is a multicenter, open-label study designed at the request of the Division of Anesthesia, Analgesia and Addiction Products of the U.S. Food and Drug Administration (FDA). The IAP312 study will enroll approximately 315 hospitalized, post-operative patients who will use Zalviso to self-administer sublingually tablets containing 15 micrograms of sufentanil as often as once every 20 minutes for 24‑to-72 hours to manage their moderate-to-severe acute pain. In addition to safety and efficacy measures, IAP312 will collect information on device usability, including any incidence of Zalviso’s failure to dispense medication as well as the incidence of misplaced or dropped tablets.